Tag Archives: Kyle Bass

PTAB Institutes Kyle Bass IPR Against Pharmaceutical Patent Based On SEC Document

Kyle Bass has filed numerous prior IPR petitions against pharmaceutical patents, some of which have been denied due to use of prior art references that were not sufficiently proven to be “publicly accessible” (see “Clinical Trials as Prior Art: PTAB Denies Bass IPR With Only A “Hope” Of Efficacy”). However, in IPR2015-01850, the PTAB instituted … Continue reading this entry

PTAB Refuses To Sanction Kyle Bass

Many pharmaceutical companies have complained about the IPR petitions filed by Kyle Bass and the Coalition for Affordable Drugs against Orange Book-listed patents covering approved pharmaceutical products, but Celgene Corp. took more serious action, and filed motions for sanctions in the IPRs launched against its patents relating to Thalomid® (thalidomide) and Revlamid® (lenalidomide). However, the USPTO Patent … Continue reading this entry

PTAB Requests Additional Briefing on Hedge Fund IPR Questions: A Decision May Be Near

On Sept. 1, 2015, the PTAB issued an order in Coalition for Affordable Drugs (CFAD) v. NPS Pharmaceuticals for the parties to brief the following questions in seven business days: “1) the standing requirement for challenging the validity of that patent in an inter partes review under 35 U.S.C. § 311(a);… Continue reading this entry

PTAB Denies Institution of Kyle Bass IPRs -- But Not for Improper Purpose

The USPTO Patent Trial and Appeal Board (PTAB) issued it first institution decisions on IPR petitions filed by Kyle Bass and his Coalition for Affordable Drugs, denying institution of his challenges to two Orange-book listed patents for Ampyra. Many were watching to see if the PTAB would render a decision based on the “improper purpose” … Continue reading this entry